Adobe (NDQ:ADBE): The 42-year old company behind PhotoShop and PDFs may have an even richer future ahead, driven by AI
Outside the so-called Magnificant Seven stocks, Adobe (NDQ:ADBE) is one of the most well-known by investors, as well as the…
Blackstone Minerals (ASX:BSX): Straw hats in winter
Blackstone Minerals (ASX:BSX): Summer is coming Back in early 2022, Blackstone Minerals was riding high. The Perth-based resource junior, at…
Private Credit: What is it and why has this US$1tn market become such a popular investment option?
Private credit is a US$1 trillion (A$1.49tn) market and $200bn in Australia alone. It is clearly worth knowing about and…
How Many Stocks Should You Have in a Portfolio?
The amount of shares to buy can be an instrumental choice that might define your investment strategy and serve as…
Challenger (ASX:CGF): Are investors panicking too much?
Shareholders in Challenger (ASX:CGF) didn’t take the news of Apollo’s sell down well. Apollo, a global fund manager, sold half…
Is the September Effect Real? Here’s What the Historical Data says and The Challenge Facing Investors
One of the perceived market phenomena is the “September Effect,” observed when the monthly returns during the month of September…
IPhone 16 Launch Event: Should You Buy Apple Stock Now
The highly awaited event of Apple witnessed the launch of the iPhone 16 series on September 9, 2024. It launches…
Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer
Unless you’re a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as…
Bio Gene Technology (ASX:BGT): Commercialising a new class of insecticides
Bio Gene Technology (ASX:BGT) ASX-listed AgTech company developing two compounds – Flavocide™ and Qcide™ – as insecticides. Investors may hear…
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…
Star Entertainment Group (ASX:SGR): Where to now in a post-COVID world? Can it avoid a looming cash crunch?
In a July interview with the AFR, Star Entertainment Group boss Steve McCann admitted that his company’s pre-pandemic glory days…
Prescient Therapeutics (ASX:PTX): About to take the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…